At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 21, 2026 at 17:35 ET
Revolution Medicines announced updated Phase 1/2 data for daraxonrasib in previously untreated metastatic pancreatic cancer, showing a 58% confirmed ORR in combination with chemotherapy and 47% in monotherapy, with manageable safety profiles. These results support ongoing Phase 3 trials in frontline PDAC, a high-unmet need indication with ~3% five-year survival.
- Daraxonrasib + GnP combination showed 58% confirmed ORR (95% CI: 41, 73) in 40 patients with metastatic PDAC
- Monotherapy arm showed 47% ORR (95% CI: 31, 64), including one complete response
- No Grade 5 treatment-related adverse events reported in either cohort
- Phase 3 RASolute 303 trial ongoing in first-line PDAC; RASolute 302 recently met PFS and OS endpoints
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access